KRAS and neoplasm: Given the emerging evidence linking the inactivation of specific tumor suppressors with unique immune microenvironments of KRAS-mutant LUAD14,31,32, we interrogated the immune cell composition of Keap1-deficient tumors using a multiparametric flow cytometry approach17.